Interestingly, by comparing HDL-CEC of treated FH patients with that of a small group of control subjects added in each experiment as internal standards, we observed similar values (AD HDL-CEC of controls: 5.9% ± 0.7, AD HDL-CEC of FH after treatment 6.0% ± 1.2, p > 0.999; ABCG1 HDL-CEC of controls: 5.2% ± 1.7, ABCG1 HDL-CEC of FH after treatment 5.6% ± 1.4, p > 0.9999; ABCA1 HDL-CEC of controls: 3.6% ± 0.6; ABCA1 of FH after treatment 3.7% ± 0.9, p > 0.9999). The gene discussed is ABCG1; the disease is familial hyperaldosteronism.